Clin2
NCT06358638Possibly a fitRecruiting

Sickle cell transplant using a gentler approach for patients with donor antibodies

Sickle Cell Disease

Treatments studied

Part of Blood & lymphatic, Genetic & congenital clinical trials.

This trial is testing a new, gentler type of bone marrow transplant for children and young adults with sickle cell disease who have a healthy sibling donor with a mismatched blood type or who have antibodies against their donor's red blood cells. The goal is to replace the faulty bone marrow with healthy donor cells, with fewer side effects than traditional transplants.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
12 people
Ages
2 years to 25 years
Study type
Interventional

Who can take part

  • You are between 2 and 24 years old and have sickle cell disease.
  • You have a healthy sibling who is a perfect match (HLA-identical) and either has a different blood type (major ABO mismatch) or you have antibodies against some of their red blood cell traits.
  • You have had at least one serious sickle cell complication like a stroke, chest crisis, or severe pain episode.
  • Your blood counts (neutrophils and platelets) are at a safe level, and you are able to perform daily activities (Lansky/Karnofsky score of 70 or higher).
  • Your heart, liver, kidneys, and lungs are working well enough (no severe organ damage).

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT03587272Recruiting· Phase 2
Sibling bone marrow transplant to reduce treatment side effects

This study tests a way to do a bone marrow (stem cell) transplant from an HLA-matched sibling in children with sickle cell disease, aiming to lower the risk of serious side effects. You may be considered if you have certain past sickle complications and your body can safely handle the transplant plan.

Washington D.C., District of Columbia
NCT07599176Recruiting· Phase 1/Phase 2
Partial stem cell transplant for sickle cell disease from matched donors

This study tests a partial stem cell transplant from a matched donor to treat sickle cell disease. It may help reduce complications like strokes, organ damage, or pain crises.

Bethesda, Maryland
NCT03214354Recruiting· Phase 2
Stem cell transplant for children with sickle cell and ABO mismatch

This trial studies a stem cell transplant approach for children with sickle cell disease, using a sibling donor whose blood type is not compatible. It aims to see if this transplant method can safely reduce serious sickle cell complications.

Calgary, Alberta
NCT06872333Recruiting· Phase 2
Stem cell transplant from a matched sibling for blood disorders

This trial tests whether a stem cell transplant from a fully matched sibling donor can help people with serious blood disorders like sickle cell disease or thalassemia. It aims to replace the faulty blood system with a healthy one from the donor.

Minneapolis, Minnesota
NCT07616154Recruiting· Phase 2
Gene-Matched Family Stem Cell Transplant for Severe Sickle Cell

This trial tests whether a stem cell transplant from a partially gene-matched family member can cure severe sickle cell disease in children and young adults. The transplant uses a new approach that may work even when a perfectly matched sibling isn't available, and it might help patients whose sickle cell is causing serious complications like strokes, organ damage, or frequent pain crises.

Memphis, Tennessee
NCT04201210Recruiting· Phase 2
Stem cell transplant study for young people with severe sickle cell

This Phase 2 study tests a type of stem cell transplant that uses donor immune cells that have been specially “tweaked” to help treat sickle cell disease. It may help prevent serious sickle cell complications, but it requires careful matching and screening of organs and pregnancy status.

Vienna

Hear when a new Sickle Cell Disease trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.